Gut bug may predict prostate cancer drug response

NCT ID NCT06242509

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 23, 2026 · Updated 1 time

Summary

This study looks at whether a specific gut bacterium, Akkermansia muciniphila, can help predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will measure levels of this bacterium in stool samples before and after treatment. The goal is to see if higher levels of this bug are linked to better treatment outcomes, potentially leading to a simple, non-invasive test to guide therapy. The study involves 52 men with metastatic castration-resistant prostate cancer starting this hormone therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital Saint Louis AP-HP
RECRUITING

Paris, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER